|
|
|
20.11.26 - 00:54
|
Mesoblast Wins Deloitte Tech Fast 50 Leadership & Enterprise Growth Award (GlobeNewswire EN)
|
|
|
NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received the Leadership & Enterprise Growth Award at the Deloitte Technology Fast 50 Australia Awards which recognizes Australia's fastest-growing technology companies and the founders, innovators and leaders shaping the future of the sector....
|
|
|
|
|
|
|
16.11.26 - 00:18
|
Mesoblast Showcased at ASX Premier Investor Day Event (GlobeNewswire EN)
|
|
|
NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it was highlighted at the Australian Securities Exchange (ASX) Investor Day in Melbourne at the session titled “Meet the CEO: Inside Australia's Listed Companies.”...
|
|
|
05.11.26 - 01:15
|
Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar (GlobeNewswire EN)
|
|
|
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it hosted a key opinion leader webinar this week titled “The Graft-versus-Host Disease Exchange - Expert Perspectives on Evolving Clinical Practice” with leading pediatric transplant and cellular-therapy specialist Dr. Susan Prockop, Associate Professor, Harvard Medical School; Attending Physician & Director, Boston Children's Hospital. Dr. Prockop provided an overview of Ryoncil® (remestemcel-L-rknd)1 as a new treatment paradigm in the management of acute graft-versus-host disease, its use as first line after steroids, highlighted case studies, and discussed results from pivotal trials....
|
|
|
|
|
02.11.26 - 00:48
|
Mesoblast Board Changes (GlobeNewswire EN)
|
|
|
NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of certain members of its Board, and reiterated its intention to add new members with the requisite global commercial experience in the biopharmaceutical sector in line with its next phase of commercial delivery and growth....
|
|
|
|
|
|
|
|
|
28.10.26 - 02:36
|
Should I buy Cochlear and Mesoblast shares with $5,000? (Fool)
|
|
|
These two companies are at different stages of their growth journeys. Here's which I'd choose for a long-term investment.
The post Should I buy Cochlear and Mesoblast shares with $5,000? appeared first on The Motley Fool Australia....
|
|
|
23.10.26 - 23:00
|
Should I invest $2,000 into Mesoblast shares? (Fool)
|
|
|
I look at whether commercial progress has made this long-awaited biotech story worth investing in today.
The post Should I invest $2,000 into Mesoblast shares? appeared first on The Motley Fool Australia....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|